Nutarniq Corp is dedicated to the research and develop targeted nutritional therapies for chronic diseases and disease complications. Our R&D process is essential to develop the latest innovative therapies to optimize the health of individuals with chronic diseases and disease complications.
Our modern lifestyle and eating habits have increased the risk of different chronic conditions. We see targeted nutritional therapies as a key opportunity to stop or reverse health conditions.
- Dr. Evan Lewis
Diabetic Neuropathy Research
Diabetes is a pandemic that affects over 415 million people worldwide. The most common complication of diabetes is neuropathy, that affects over 50% of people with diabetes within 10-years of diagnosis. Diabetic neuropathy is nerve damage caused by high blood sugar, high blood pressure, which results in painful symptoms and the loss of sensation starting in the hands and feet. Current pharmacotherapies can control blood sugar and blood pressure but cannot stop or reverse nerve damage.
Nutarniq CEO, Dr. Evan Lewis lead the first clinical trial that has shown nerve regeneration in patients with diabetes and neuropathy. Frontline Neuropathy was developed from this research. Here is a summary:
Other Research Areas
Our R&D team is continually working on new products to help optimize the health of people with chronic diseases and disease complications. The Nutarniq pipeline shows what we have in development.